NVAX - NASDAQ
Novavax, Inc.
$10.57
+3.6%Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
At a Glance
Live SnapshotNovavax, Inc. Management Team
Ms. Erika S. Trahan
Associate Director of Investor & Public Relations
Mr. Ian J. Watkins
Executive Vice President & Chief Human Resources Officer
Mr. Richard P. Crowley
Executive Vice President & Chief Operating Officer
Dr. Henrietta Ukwu FACP FRAPS, M.D.
Executive Vice President & Chief Regulatory Officer
Ms. Elaine O'Hara
Executive Vice President & Chief Strategy Officer
Compensation
$991,316
Ms. Silvia Taylor M.B.A.
Executive Vice President and Chief Corporate Affairs & Advocacy Officer
Mr. James Patrick Kelly C.F.A.
Executive Vice President, Chief Financial Officer & Treasurer
Compensation
$880,849
Mr. John Joseph Trizzino B.S., M.B.A.
President & Chief Operating Officer
Compensation
$857,257
Mr. John Charles Jacobs M.B.A.
President, Chief Executive Officer & Director
Compensation
$1,550,611
Mr. Troy Morgan Esq., J.D.
Senior Vice President, Deputy General Counsel & Chief Compliance Officer
Novavax, Inc. Insider Positioning
During the last 12 months, there has been no insider trading activity reported for NVAX.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.
Insider Participation
No insider trading activity reported from any insiders in the past year.
SEC Filings
NVAX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 18, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 20, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | June 13, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 28, 2023 | April 28, 2023 | ||
DEF 14A DEF 14A 2021 N/A | May 02, 2022 | June 16, 2021 | 2021 | |
DEF 14A DEF 14A 2021 N/A | May 03, 2021 | June 17, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | May 13, 2020 | June 25, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | May 16, 2019 | June 28, 2019 | 2019 | |
DEF 14A DEF 14A 2019 N/A | April 01, 2019 | May 08, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 30, 2018 | June 14, 2018 | 2018 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.